Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database
Status:
Completed
Trial end date:
2017-09-29
Target enrollment:
Participant gender:
Summary
The patients included in this observational study will be drawn from a research database
containing claims and enrollment data for members of a large, geographically diverse US
health plan. The objective of this study is to estimate the rate of serious infections,
tuberculosis, malignancies, and other outcomes in psoriasis patients treated with
ustekinumab, anti-tumor necrosis factor (TNF) biologics, non-anti-TNF biologics, or systemic
non-biological treatments.